dyphylline

Trade name: neothylline

Small moleculeapproved

Approved

Mar 7, 1951

Dyphylline is 7-(2,3-dihydroxypropyl)-theophylline, a white, extremely bitter, amorphous powder that is freely soluble in water and soluble in alcohol. Dyphylline is stable in gastrointestinal fluids over a wide range of pH. Dyphylline is a xanthine derivative with pharmacologic actions similar to theophylline and other members of this class of drugs. Its primary action is that of bronchodilation, but it also exhibits peripheral vasodilatory and other smooth muscle relaxant activity to a lesser degree. The bronchodilatory action of dyphylline, as with other xanthines, is thought to be mediated through competitive inhibition of phosphodiesterase with a resulting increase in cyclic AMP producing relaxation of the bronchial smooth muscle. Dyphylline exerts its bronchodilatory effects directly and, unlike theophylline, is excreted unchanged by the kidneys without being metabolized by the liver. Because of this, dyphylline pharmacokinetics and plasma levels are not influenced by various factors that affect liver function and hepatic enzyme activity, such as smoking, age, congestive heart failure, or concomitant use of drugs which affect liver function. — NCATS

Clinical trial activity

0 trials · 0 clinical orgs · 4 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Timeline

1950s

Mar 7, 1951
Teva — Earliest FDA Approval
Mar 7, 1951
Teva — NDA Secondary Org
Mar 7, 1951
Teva — NDA Organization

1970s

Aug 16, 1976
Mylan — Marketing Organization
Aug 16, 1976
Savage Labs — Marketing Organization
Aug 16, 1976
PHARMOBEDIENT — Marketing Organization

Indications

Approved for

Mechanism of action

Phosphodiesterase 3AINHIBITOR
PDE3A inhibitor
- cGMP-inhibited 3',5'-cyclic phosphodiesterase A (PDE3A) ↗
Phosphodiesterase 4INHIBITOR
Phosphodiesterase 4 inhibitor

Approval history

approvedMar 7, 1951

Chemistry & pharmacology

Loading structure…

SMILES

CN1C2=C(N(CC(O)CO)C=N2)C(=O)N(C)C1=O

Mol. weight: 254.2426 g/mol
Lipinski Ro5: Pass
Rule of 3: No
Chirality: Racemic Mixture
Inorganic: No
Polymer: No
Delivery: Oral, Parenteral
Availability: Discontinued

Oral

Yes

Parenteral

Yes

Topical

Sources

Also known as

(1,2-dihydroxy-3-propyl)thiophyllin
(1,2-dihydroxy-3-propyl)thiophyllin
1,3-dimethyl-7-(2,3-dihydroxypropyl)xanthine
1,3-dimethyl-7-(2,3-dihydroxypropyl)xanthine
7-(2,3-dihydroxypropyl)-1,3-dimethylxanthine
7-(2,3-dihydroxypropyl)-1,3-dimethylxanthine
7-(2,3-dihydroxypropyl)-3,7-dihydro-1,3-dimethyl-1h-purine-2,6-dione
7-(2,3-dihydroxypropyl)-3,7-dihydro-1,3-dimethyl-1h-purine-2,6-dione
(+-)-7-(2,3-dihydroxypropyl)theophylline
(+-)-7-(2,3-dihydroxypropyl)theophylline
7-(2,3-dihydroxypropyl)theophylline
7-(2,3-dihydroxypropyl)theophylline
7-(beta,gamma-dihydroxypropyl)theophylline
7-(beta,gamma-dihydroxypropyl)theophylline
7-(β,γ-dihydroxypropyl)theophylline
7-(β,γ-dihydroxypropyl)theophylline
aristophyllin
corphyllin
dihydroxypropyl theopylin
dihydroxypropyl theopylin
dilor
dilor
dilor-400
dilor-400
diphyllin
diphylline
diprofilina
diprofilina
diprophyllin
diprophylline
diprophylline
diprophylline
diprophylline
diprophylline
(+-)-diprophylline
(+-)-diprophylline
(±)-diprophylline
(±)-diprophylline
diprophyllinum
diprophyllinum
dyphylline
dyphylline
dyphylline
dyphylline
dyphylline
dyphylline
dyphylline
dyphylline
dyphylline
(+-)-dyphylline
(+-)-dyphylline
(±)-dyphylline
(±)-dyphylline
glyphyllin
glyphylline
glyphylline
glyphylline
hidroxiteofillina
lufyllin
lufyllin
neophyllin
neothylline
neothylline
neutrafillina
neutraphyllin
neutraphylline
neutroxantina
propyphyllin
protheophylline
synthophylline

Organizations

Marketing (5)

Organization	Org type	Relationship	Date
Mylan	For profit	MKTG	Aug 16, 1976
PHARMOBEDIENT	For profit	MKTG	Aug 16, 1976
Savage Labs	For profit	MKTG	Aug 16, 1976
Teva	For profit	NDA2	Mar 7, 1951
Teva	For profit	NDA	Mar 7, 1951